Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)

NCT05249920 is registered in ClinicalTrials.gov with Beijing Tiantan Hospital as lead sponsor.

NCT NCT05249920
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05249920 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment of Acute Ischemic STroke With Edaravone Dexborneol Ⅱ (TASTE-2)
Lead sponsor
Beijing Tiantan Hospital
Phase
Phase 3
Overall status
Completed
Start date
March 18, 2022
Completion date
May 19, 2023
Enrollment
1,362 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute ischemic stroke, edaravone dexborneol, mechanical thrombectomy, phase iii